Alpha Tau Medical Ltd. (DRTS) Stock Price & Analysis
Alpha Tau Medical Ltd. (DRTS) is trading at USD 12.08, down 0.08% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.
DRTS last closed at USD 12.08; today's session has ranged USD 11.82–12.22 on volume of 530,909 shares. Market capitalization is —, with a 52-week range of USD 3.43–15.79 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.
What changed for DRTS since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- Alpha Tau Medical Ltd. (DRTS) stock went from USD 3.42 (close of the week of Aug 25, 2025, split-adjusted) to USD 12.08, a +253.2% price change; the S&P 500 (SPY) moved +14.9% over the same period.
- In the latest 13F period (Q3 2026), 1 of 80 superinvestors tracked by Nexqual hold DRTS; 0 opened new positions, 0 added and 1 reduced.
Also available as compact Markdown for AI agents: nexqual.com/DRTS.md
Key facts (DRTS)
- 1 of 80 tracked superinvestors hold DRTS (13F, Q3 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $1.6M; 1 not under a Rule 10b5-1 plan ($352K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +228.3% vs S&P 500 +11.9%; 5Y +21.9% vs S&P 500 +66.7%.
- Next earnings: 2026-11-19 (date not yet confirmed by the company), EPS estimate USD -0.15, revenue estimate $167K. All companies reporting that day: https://nexqual.com/earnings/2026-11-19
- Dividend: DRTS paid no cash dividend in the last five years.
- Short interest: 6.10% of float (as of 2026-10-30), 8.6 days to cover.
Superinvestors (SEC 13F-HR, Q3 2026) (DRTS)
1 of 80 tracked investors hold DRTS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.04% | $3.2M | Reduced -2.0% |
Insider sales (SEC Form 4, open-market, last ~7 months) (DRTS)
8 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Levy Raphi | Chief Financial Officer | 2,871 | $43K | 3.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Levy Raphi | Chief Financial Officer | 17,730 | $248K | 16.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-06 | Levy Raphi | Chief Financial Officer | 2,270 | $32K | 2.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-02 | Levy Raphi | Chief Financial Officer | 17,873 | $232K | 16.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Levy Raphi | Chief Financial Officer | 2,127 | $28K | 2.3% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-30 | Levy Raphi | Chief Financial Officer | 20,000 | $240K | 18.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-25 | Levy Raphi | Chief Financial Officer | 20,000 | $220K | 15.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-23 | Levy Raphi | Chief Financial Officer | 17,500 | $167K | 11.8% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-03 | Levy Raphi | Chief Financial Officer | 32,500 | $352K | 18% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Total return (dividends reinvested) (DRTS)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | +228.3% | +21.9% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | +228.5% | +4.0% |
| Volatility (annualized) | 76.2% | 70.3% |
| Max drawdown | -23.9% (Feb 2026→Mar 2026) | -84.8% (Mar 2022→Aug 2024) |
Dividends (DRTS)
DRTS paid no cash dividend in the last five years.
Short interest (DRTS)
3,920,240 shares sold short, 6.10% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 3,447,381 shares (+13.7%). Days to cover: 8.6 (short shares ÷ average daily volume).
DRTS earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.50 | −$0.14 | Miss −257.1% | — |
| — | Quarter ended Mar 31, 2026 | −$0.26 | −$0.12 | Miss −116.7% | — |
| — | Quarter ended Dec 31, 2025 | −$0.14 | −$0.12 | Miss −16.7% | — |
| — | Quarter ended Sep 30, 2025 | −$0.14 | −$0.12 | Miss −16.7% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
DRTS recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | 6-K | Current report (foreign issuer) · period ended Nov 16, 2026 |
| Nov 16, 2026 | 6-K | Current report (foreign issuer) · period ended Nov 16, 2026 |
| Nov 12, 2026 | 6-K | Current report (foreign issuer) · period ended Nov 12, 2026 |
| Oct 29, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 29, 2026 |
| Oct 22, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 22, 2026 |
| Oct 19, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 19, 2026 |
| Aug 31, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 31, 2026 |
| Aug 10, 2026 | 6-K | Current report (foreign issuer) · period ended Jun 30, 2026 |
| Aug 10, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 10, 2026 |
| Jul 21, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 21, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
DRTS suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | HekaBio | “in our core markets, including the United States and Europe, except for our agreement with HekaBio KK with respect to the commercialization” |
| Partner | MIM Software | “and patent applications related to our Alpha DaRT technology and, other than our collaboration agreement with MIM Software Inc. ("MIM")” |
| Partner | Althera Medical | “In addition, under the intellectual property purchase agreement with Althera, we assumed all of Althera's liabilities towards the” |
| Partner | Oramed | “For example on April 24, 2025, we entered into the Oramed Purchase Agreement with Oramed for the sale by us of 14,110,121 Shares, in a” |
Quoted from the company's 20-F filed Mar 9, 2026.
Companies that name DRTS in their SEC reports
| Relationship to DRTS | Company | Filing | Sentence |
|---|---|---|---|
| partner | ORAMED PHARMACEUTICALS INC. (ORMP) | 10-K Mar 26, 2026 | “subsidiary, Oramed Ltd entered into a share purchase agreement with Alpha Tau Medical Ltd. (Nasdaq: DRTS), or Alpha Tau, a clinical-stage” |
DRTS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.15 | $-0.14 | −$0.01 | $166,670 | 4 |
| Next quarter (ends Dec 2026) | $-0.16 | $-0.15 | −$0.01 | $333,330 | 4 |
| Current fiscal year (ends Dec 2026) | $-0.96 | $-0.88 | −$0.09 | $500,000 | 5 |
| Next fiscal year (ends Dec 2027) | $-0.54 | $-0.53 | −$0.01 | $10.7M | 5 |
DRTS options: expected move
Options price a move of about ±7.7% (±$0.93) by Nov 20, 2026, which includes earnings on Nov 19, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 2 | 106.7% | ±7.7% |
| Dec 18, 2026 | 30 | 76.4% | ±18.2% |
| Jan 15, 2027 | 58 | 72.3% | ±23.6% |
| Feb 19, 2027 | 93 | 64.7% | ±26.5% |
| May 21, 2027 | 184 | 66.8% | ±38.0% |
30-day implied volatility 69.5% vs 59.6% realized over the last 30 trading days. Put/call ratio (volume) 0.13. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 18, 2026 at 20:43 UTC)
| Price | USD 12.08 |
|---|---|
| Change | ▼ 0.08% (down) |
| Previous Close | USD 12.08 |
| Open | USD 12.08 |
| Day Range | USD 11.82 – 12.22 |
| 52-Week Range | USD 3.43 – 15.79 |
| Volume | 530,909 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (DRTS)
Nexqual's technical model rates DRTS "SELL" based on 1 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.4 (neutral) |
| vs SMA50 | Below (USD 13.9) |
| MACD | -0.33 (negative) |
Earnings (DRTS)
| Next Earnings Date | 2026-11-19 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $166,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.5 vs est -0.14 ▼ miss |
| 2026-03-31 | USD -0.26 vs est -0.12 ▼ miss |
| 2025-12-31 | USD -0.14 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.12 ▼ miss |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financials & Fundamentals (DRTS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -141.68% |
| Debt / Equity | 0.34 |
| Current Ratio | 11.09 |
| Total Cash | $100.64M |
| Total Debt | $15.15M |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financial Health Score (DRTS)
Nexqual rates Alpha Tau Medical Ltd.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $101M cash vs $15M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$13M (TTM) |
| Efficiency | Critical — ROE -142%, ROA -25.7% |
Ownership (DRTS)
| Insider Ownership | +30.50% |
|---|---|
| Institutional Ownership | +12.01% |
| Shares Outstanding | 92.48M |
| Float | 64.10M |
| Short % of Float | +6.10% |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 98.14 | ▲ 1.38% |
| BLTE | Belite Bio, Inc | USD 157.14 | ▼ 0.37% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.92 | ▼ 0.42% |
| IMVT | Immunovant, Inc. | USD 33.3 | ▲ 0.27% |
| AXSM | Axsome Therapeutics, Inc. | USD 133.9 | ▼ 1.51% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.19% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt